Aquestive Therapeutics is a pharmaceutical company that develops and manufactures medicines using proprietary delivery technologies designed to replace invasive or inconvenient standard therapies. The company operates manufacturing facilities in Indiana and headquarters in New Jersey, producing four licensed commercial products for global licensees, most notably Suboxone sublingual film for opioid-use disorder treatment. Aquestive's core innovation is its PharmFilm platform—a polymer-based oral film technology enabling fast-acting drug delivery through the mouth or cheek—along with its AdrenaVerse epinephrine prodrug platform; lead proprietary products include Anaphylm, a non-device oral epinephrine film for anaphylaxis, and Libervant, an FDA-approved seizure-rescue therapy for young children. The company generates revenue from manufacturing fees and royalties on licensed products, combined with development milestone payments and future commercial potential from its proprietary pipeline programs targeting severe allergic reactions, epilepsy, and other conditions where device-free or faster delivery offers clinical advantages over current standard-of-care therapies.